AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by research analysts at J P Morgan Chase & Co in a report issued on Thursday. They presently have a GBX 4,500 ($58.12) price target on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target suggests a potential downside of 4.65% from the company’s previous close.

AZN has been the topic of several other reports. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Deutsche Bank AG decreased their price target on shares of AstraZeneca plc from GBX 5,700 ($73.61) to GBX 5,300 ($68.45) and set a “buy” rating on the stock in a report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a report on Tuesday, August 8th. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a GBX 5,000 ($64.57) price target on shares of AstraZeneca plc in a report on Monday, June 19th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of GBX 5,022.91 ($64.87).

Shares of AstraZeneca plc (LON AZN) traded down 1.80% during trading on Thursday, hitting GBX 4719.50. 3,225,455 shares of the stock were exchanged. The firm has a 50 day moving average price of GBX 4,556.15 and a 200 day moving average price of GBX 4,880.61. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The firm’s market capitalization is GBX 59.75 billion.

COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Stock Rating Reaffirmed by J P Morgan Chase & Co” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/17/astrazeneca-plc-azn-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

In related news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.